The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin Martin HoeniglRosanne SpruteJeffrey D. Jenks Leading Article Open access 09 October 2021 Pages: 1703 - 1729
Targeting the Angiopoietin/Tie Pathway: Prospects for Treatment of Retinal and Respiratory Disorders Racheal Grace AkwiiConstantinos M. Mikelis Review Article 29 September 2021 Pages: 1731 - 1749
Bimekizumab for the Treatment of Psoriasis Egídio FreitasAndrew BlauveltTiago Torres Review Article 08 October 2021 Pages: 1751 - 1762
REal worlD Effectiveness and Safety of Mepolizumab in a Multicentric Spanish Cohort of Asthma Patients Stratified by Eosinophils: The REDES Study Christian Domingo RibasTeresa Carrillo Díazthe REDES Study Group Original Research Article Open access 29 September 2021 Pages: 1763 - 1774
Odevixibat: First Approval Emma D. Deeks AdisInsight Report Open access 09 September 2021 Pages: 1781 - 1786
Avalglucosidase alfa: First Approval Sohita Dhillon AdisInsight Report 30 September 2021 Pages: 1803 - 1809
Correction to: Tralokinumab: First Approval Sean Duggan Correction Open access 17 September 2021 Pages: 1811 - 1811
Correction to: Tralokinumab: First Approval Sean Duggan Correction Open access 24 September 2021 Pages: 1813 - 1813
Correction to: Odevixibat: First Approval Emma D. Deeks Correction Open access 23 September 2021 Pages: 1815 - 1815
Correction to: Netupitant/Palonosetron: A Review in Chemotherapy-Induced Nausea and Vomiting Matt Shirley Correction Open access 24 September 2021 Pages: 1817 - 1817
Correction to: Hyperkalemia in Chronic Kidney Disease in the New Era of Kidney Protection Therapies José M. ValdivielsoOlga BalafaAlberto Ortiz Correction 11 October 2021 Pages: 1819 - 1819
